Halozyme Therapeutics (HALO) Tops Q2 EPS by 14c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $125.63 +0.88%
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.74, $0.14 better than the analyst estimate of $0.60. Revenue for the quarter came in at $221 million versus the consensus estimate of $199.95 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 EPS of $2.65-$2.75, versus the consensus of $2.61. Halozyme Therapeutics sees FY2023 revenue of $825-845 million, versus the consensus of $823 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Preferred Bank (PFBC) Tops Q3 EPS by 4c
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
